Application segmentation delineates the primary clinical drivers of the Scalp Microneedling market. Hair regrowth accounts for the largest share, estimated at roughly 55 % of total revenue, as it targets androgenic alopecia and telogen effluvium through follicular stimulation. Scalp health—encompassing seborrheic dermatitis mitigation, barrier repair, and microcirculation enhancement—contributes about 30 % of market size, reflecting growing consumer focus on scalp wellness beyond hair density. The drug‑delivery niche, representing approximately 15 % of sales, leverages microneedle channels to administer topical actives such as minoxidil, peptides, or stem‑cell extracts, adding a premium layer to device pricing. Together these applications define the overall market landscape, and their relative weight informs product development, pricing strategy, and investment allocation within the broader Scalp Microneedling segmentation framework.